BRPI0920973B8 - composição aquosa contendo hormônio estimulanete de folículos - Google Patents

composição aquosa contendo hormônio estimulanete de folículos

Info

Publication number
BRPI0920973B8
BRPI0920973B8 BRPI0920973A BRPI0920973A BRPI0920973B8 BR PI0920973 B8 BRPI0920973 B8 BR PI0920973B8 BR PI0920973 A BRPI0920973 A BR PI0920973A BR PI0920973 A BRPI0920973 A BR PI0920973A BR PI0920973 B8 BRPI0920973 B8 BR PI0920973B8
Authority
BR
Brazil
Prior art keywords
stimulating hormone
composition containing
aqueous composition
follicle stimulating
containing follicle
Prior art date
Application number
BRPI0920973A
Other languages
English (en)
Inventor
Asada Hajme
Kataoka Hiroshige
Original Assignee
Aska Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharm Co Ltd filed Critical Aska Pharm Co Ltd
Publication of BRPI0920973A2 publication Critical patent/BRPI0920973A2/pt
Publication of BRPI0920973B1 publication Critical patent/BRPI0920973B1/pt
Publication of BRPI0920973B8 publication Critical patent/BRPI0920973B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição aquosa estáveis contendo hormônio estimulador de folículos, que consiste de hormônio estimulador estimulador de folículos e histidina como agente estabilizador.
BRPI0920973A 2008-11-04 2009-11-02 composição aquosa contendo hormônio estimulanete de folículos BRPI0920973B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2008-283079 2008-11-04
JP2008283079 2008-11-04
JP2009216563 2009-09-18
JP2009-216563 2009-09-18
PCT/JP2009/005809 WO2010052879A1 (ja) 2008-11-04 2009-11-02 卵胞刺激ホルモン含有水性組成物

Publications (3)

Publication Number Publication Date
BRPI0920973A2 BRPI0920973A2 (pt) 2016-01-05
BRPI0920973B1 BRPI0920973B1 (pt) 2021-02-23
BRPI0920973B8 true BRPI0920973B8 (pt) 2021-05-25

Family

ID=42152693

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920973A BRPI0920973B8 (pt) 2008-11-04 2009-11-02 composição aquosa contendo hormônio estimulanete de folículos

Country Status (13)

Country Link
US (1) US8329649B2 (pt)
EP (1) EP2366401B1 (pt)
JP (1) JP5554244B2 (pt)
KR (1) KR101668502B1 (pt)
CN (1) CN102202682B (pt)
AU (1) AU2009312235B2 (pt)
BR (1) BRPI0920973B8 (pt)
CA (1) CA2742659C (pt)
ES (1) ES2548378T3 (pt)
IL (1) IL212641A (pt)
MX (1) MX2011004453A (pt)
RU (1) RU2561057C2 (pt)
WO (1) WO2010052879A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5554244B2 (ja) * 2008-11-04 2014-07-23 あすか製薬株式会社 卵胞刺激ホルモン含有水性組成物
LT2568806T (lt) 2010-05-12 2016-09-26 Radius Health, Inc. Terapiniai režimai
EP3332799A1 (en) * 2011-04-22 2018-06-13 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
IN2013MU03559A (pt) * 2013-11-12 2015-07-24 Cadila Healthcare Ltd
RS64115B1 (sr) 2014-03-28 2023-04-28 Univ Duke Lečenje kancera dojke upotrebom selektivnih modulatora receptora estrogena
IL310069B2 (en) 2015-04-29 2025-08-01 Radius Pharmaceuticals Inc Rad1901 for use in the treatment of cancer
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
CN117417263A (zh) 2017-01-05 2024-01-19 雷迪厄斯制药公司 Rad1901-2hcl的多晶型形式
KR102792490B1 (ko) 2018-07-04 2025-04-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
JP7667083B2 (ja) 2019-02-12 2025-04-22 ラジウス ファーマシューティカルズ，インコーポレイテッド 方法および化合物
WO2021107033A1 (ja) * 2019-11-29 2021-06-03 千寿製薬株式会社 医薬組成物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1985644U (de) 1968-01-20 1968-05-22 Broekelmann Jaeger & Busse K G Luesterklemmengehaeuse.
US4114743A (en) 1976-05-03 1978-09-19 Dana Corporation Fluid actuated operator and clutch linkage
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4440679A (en) 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
IT1240314B (it) * 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
US5140010A (en) 1989-09-28 1992-08-18 Immunobiology Research Institute Stabilized aqueous formulations of thymopentin
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
JPH08333277A (ja) * 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤
IL122732A0 (en) 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
DE19856443A1 (de) 1998-12-08 2000-06-21 Centeon Pharma Gmbh Stabilisiertes Antithrombin III-Präparat
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
EP1336410A4 (en) * 2000-08-04 2005-10-12 Chugai Pharmaceutical Co Ltd PROTEIN INJECTION PREPARATIONS
EP1610822B2 (en) * 2003-04-02 2018-09-19 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
ES2358330T5 (es) * 2003-04-02 2018-12-03 Ares Trading S.A. Formulaciones farmacéuticas líquidas de FSH y LH junto con un tensioactivo no iónico
US8053599B2 (en) * 2003-10-03 2011-11-08 Ono Pharmaceutical Co., Ltd. Drug containing (2R)-2-propyloctanoic acid as the active ingredient
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
KR101105871B1 (ko) 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
JP4502017B2 (ja) 2008-01-25 2010-07-14 富士ゼロックス株式会社 色材記録装置、色材記録プログラム、及び画像形成装置
JP5554244B2 (ja) * 2008-11-04 2014-07-23 あすか製薬株式会社 卵胞刺激ホルモン含有水性組成物

Also Published As

Publication number Publication date
EP2366401A1 (en) 2011-09-21
WO2010052879A1 (ja) 2010-05-14
CA2742659A1 (en) 2010-05-14
CN102202682B (zh) 2015-08-19
AU2009312235A1 (en) 2011-06-30
KR20110093812A (ko) 2011-08-18
IL212641A0 (en) 2011-07-31
CA2742659C (en) 2016-09-27
CN102202682A (zh) 2011-09-28
KR101668502B1 (ko) 2016-10-21
EP2366401A4 (en) 2012-08-08
US20110275567A1 (en) 2011-11-10
RU2561057C2 (ru) 2015-08-20
JP5554244B2 (ja) 2014-07-23
MX2011004453A (es) 2011-08-12
EP2366401B1 (en) 2015-07-15
AU2009312235B2 (en) 2014-01-16
US8329649B2 (en) 2012-12-11
JPWO2010052879A1 (ja) 2012-04-05
RU2011122629A (ru) 2012-12-20
ES2548378T3 (es) 2015-10-16
BRPI0920973B1 (pt) 2021-02-23
IL212641A (en) 2013-10-31
BRPI0920973A2 (pt) 2016-01-05

Similar Documents

Publication Publication Date Title
BRPI0920973B8 (pt) composição aquosa contendo hormônio estimulanete de folículos
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
PE20150200A1 (es) Formulacion de anticuerpos
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
CL2010001428A1 (es) Compuestos derivados de amidas y tioamidas heteroaromaticas; agente que contiene al menos uno de dichos compuestos; procedimiento para combatir parasitos; y uso de dichos compuestos.
CL2015002519A1 (es) Composiciones antimicrobiales y procedimientos de uso relacionados.
ECSP077299A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos
BR112014029906A2 (pt) composições compreendendo um agente de controle biológico e um inseticida.
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
MX2011009131A (es) Composiciones aditivas espesantes.
CR20110043A (es) Mezclas fungicidas que comprenden 1-metilpirazol-4-ilcarboxanilidas sustituidas
CL2008001124A1 (es) Formulacion farmaceutica que comprende al menos un derivado de acido lipoico y un reactivo formador de par ionico, util en el tratamiento del cancer.
MX2015011520A (es) Composiciones antimicrobianas.
GT201200276A (es) Combinaciones de compuestos activos
BR112014029222A2 (pt) composições que compreendem um agente de controle biológico e um inseticida
BR112015000520A2 (pt) agente de espessamento estável com lipase
EA201071166A1 (ru) Контролируемое высвобождение активных агентов из олеосом
SMP201600230B1 (it) Composizione cosmetica
EP2377849A4 (en) CHEMICAL INHIBITOR OF THE P53 SNAIL BINDING AND PHARMACEUTICAL COMPOSITION FOR TUMOR TREATMENT WITH THE INHIBITOR AS AN ACTIVE SUBSTANCE
CL2010001620A1 (es) Composicion agricola, del cuidado personal, del cuidado de la casa y de revestimiento que comprende silicona y otro componente adicional; emulsion acuosa y no acuosa que comprende la composicion agricola; y metodo para formular dichas composiciones (div. sol. n° 656-207).
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
CL2015002721A1 (es) Formulaciones oftálmicas
DOP2016000007A (es) Pirazolpiridinas sustituidas
CO6351779A2 (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos
CR20110660A (es) Mezclas fungicidas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF